Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1952 1
1956 1
1957 1
1959 1
1960 1
1961 1
1962 1
1963 1
1964 2
1965 3
1966 5
1967 3
1968 5
1969 14
1970 21
1971 25
1972 23
1973 38
1974 29
1975 23
1976 32
1977 35
1978 25
1979 37
1980 23
1981 27
1982 30
1983 44
1984 27
1985 48
1986 50
1987 36
1988 48
1989 70
1990 56
1991 58
1992 37
1993 47
1994 50
1995 46
1996 31
1997 33
1998 24
1999 26
2000 31
2001 28
2002 20
2003 26
2004 21
2005 30
2006 27
2007 22
2008 19
2009 20
2010 23
2011 20
2012 24
2013 21
2014 17
2015 15
2016 15
2017 15
2018 18
2019 15
2020 11
2021 7
2022 2
2023 7
2024 12
2025 5
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,558 results

Results by year

Filters applied: . Clear all
Page 1
Adverse Effects of Physostigmine.
Arens AM, Kearney T. Arens AM, et al. J Med Toxicol. 2019 Jul;15(3):184-191. doi: 10.1007/s13181-019-00697-z. Epub 2019 Feb 11. J Med Toxicol. 2019. PMID: 30747326 Free PMC article. Review.
Physostigmine is underutilized following the publication of patients with sudden cardiac arrest after physostigmine administration in patients with tricyclic antidepressant (TCA) overdoses. We completed a narrative literature review to identify reported adver …
Physostigmine is underutilized following the publication of patients with sudden cardiac arrest after physostigmine adminis …
Phenserine.
Klein J. Klein J. Expert Opin Investig Drugs. 2007 Jul;16(7):1087-97. doi: 10.1517/13543784.16.7.1087. Expert Opin Investig Drugs. 2007. PMID: 17594192 Review.
Phenserine, a derivative of physostigmine, was first described as an inhibitor of acetylcholinesterase (AChE) and was shown to improve cognition in various experimental paradigms in rodents and dogs. ...
Phenserine, a derivative of physostigmine, was first described as an inhibitor of acetylcholinesterase (AChE) and was shown to improv …
Physostigmine antagonizes ketamine.
Toro-Matos A, Rendon-Platas AM, Avila-Valdez E, Villarreal-Guzman RA. Toro-Matos A, et al. Anesth Analg. 1980 Oct;59(10):764-7. Anesth Analg. 1980. PMID: 6999946 Clinical Trial.
In a random cross-over double-blind trial, the effects of intravenous physostigmine salicylate (2.0 mg) and placebo were observed in seven healthy volunteers 10 minutes after the intravenous administration of 1.5 mg/kg of ketamine. ...Nausea and vomiting were signif …
In a random cross-over double-blind trial, the effects of intravenous physostigmine salicylate (2.0 mg) and placebo were observed in …
Potential pharmacotherapy of Alzheimer disease. A comparison of various forms of physostigmine administration.
Becker R, Giacobini E, Elble R, McIlhany M, Sherman K. Becker R, et al. Acta Neurol Scand Suppl. 1988;116:19-32. doi: 10.1111/j.1600-0404.1988.tb07983.x. Acta Neurol Scand Suppl. 1988. PMID: 3043998 Review.
This paper reviews clinical trials with physostigmine administered to Alzheimer patients using three different routes of administration: oral, i.v. and intracerebroventricular (i.c.v.). ...Particular emphasis is given to a novel type of physostigmine admin …
This paper reviews clinical trials with physostigmine administered to Alzheimer patients using three different routes of administr …
Pharmacokinetics of physostigmine after intravenous, intramuscular and subcutaneous administration in surgical patients.
Hartvig P, Wiklund L, Lindström B. Hartvig P, et al. Acta Anaesthesiol Scand. 1986 Feb;30(2):177-82. doi: 10.1111/j.1399-6576.1986.tb02392.x. Acta Anaesthesiol Scand. 1986. PMID: 3705906
After intravenous administration physostigmine had a very rapid plasma elimination with a plasma clearance ranging from 47 to 163 l/h with a mean +/- s.d. of 92.5 +/- 37.7 l/h. ...After administration of 1 mg physostigmine salicylate i.v., drug-induced …
After intravenous administration physostigmine had a very rapid plasma elimination with a plasma clearance ranging from 47 to …
Cardiovascular effects elicited by central administration of physostigmine via M2 muscarinic receptors in conscious cats.
Ally A, Wilson LB, Nóbrega AC, Mitchell JH. Ally A, et al. Brain Res. 1995 Apr 24;677(2):268-76. doi: 10.1016/0006-8993(95)00171-l. Brain Res. 1995. PMID: 7552252
Also, the pre-administration of the M2 muscarinic antagonist, methoctramine (25 micrograms; i.c.v.), antagonized the cardiovascular effects of physostigmine without altering the baseline variables. ...In addition, anesthesia reverses the effects elicited by the cent …
Also, the pre-administration of the M2 muscarinic antagonist, methoctramine (25 micrograms; i.c.v.), antagonized the cardiovascular e …
Assessing physostigmine's contraindication in cyclic antidepressant ingestions.
Suchard JR. Suchard JR. J Emerg Med. 2003 Aug;25(2):185-91. doi: 10.1016/s0736-4679(03)00169-0. J Emerg Med. 2003. PMID: 12902007 Review.
Ingestion of cyclic antidepressant medications or prolongation of the electrocardiographic QRS interval are commonly considered as contraindications to the use of physostigmine as an antidote for antimuscarinic toxicity. This dictum seems to stem from a few well-publicized …
Ingestion of cyclic antidepressant medications or prolongation of the electrocardiographic QRS interval are commonly considered as contraind …
Rivastigmine for the management of anticholinergic delirium.
Chiew AL, Holford AG, Chan BSH, Isoardi KZ. Chiew AL, et al. Clin Toxicol (Phila). 2024 Feb;62(2):82-87. doi: 10.1080/15563650.2024.2319854. Epub 2024 Mar 11. Clin Toxicol (Phila). 2024. PMID: 38465631
Forty-three patients (86 per cent) were treated with physostigmine before rivastigmine administration. Twenty-two were managed with transdermal rivastigmine (most commonly 9.5 mg/24 hour patch), and 28 with oral rivastigmine 6 mg. ...No patients had bradycardia or g …
Forty-three patients (86 per cent) were treated with physostigmine before rivastigmine administration. Twenty-two were managed …
The effects of physostigmine on acetylcholinesterase activity of CSF plasma and brain. A comparison of intravenous and intraventricular administration in beagle dogs.
Mattio T, McIlhany M, Giacobini E, Hallak M. Mattio T, et al. Neuropharmacology. 1986 Oct;25(10):1167-77. doi: 10.1016/0028-3908(86)90166-8. Neuropharmacology. 1986. PMID: 3785584
The activity of AChE in plasma was only minimally inhibited by intraventricular administration of physostigmine. A different response was obtained following intravenous administration of physostigmine (250-1000 micrograms). ...This study suggests that …
The activity of AChE in plasma was only minimally inhibited by intraventricular administration of physostigmine. A different r …
Toxicity study of continuous administration of physostigmine salicylate.
Lim DK, Ito Y, Stewart T, Hoskins B, Ho IK. Lim DK, et al. Pharmacol Biochem Behav. 1988 Nov;31(3):627-31. doi: 10.1016/0091-3057(88)90241-9. Pharmacol Biochem Behav. 1988. PMID: 3251246
The present study demonstrates that continuous administration with physostigmine salicylate (0.12 or 0.24 mg/kg/hr via mini-osmotic pumps) induces toxicities (e.g., body weight loss, decreased water consumption, tremors, decreased body temperatures, mortality) in gu …
The present study demonstrates that continuous administration with physostigmine salicylate (0.12 or 0.24 mg/kg/hr via mini-os …
1,558 results